ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

September 18, 2015

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions
Advanced Solid TumorsUndifferentiated Pleomorphic SarcomaSquamous Cell Carcinoma of the Head and NeckCarcinoma of the Breast
Interventions
DRUG

ABBV-085

Administered as an intravenous infusion in 28-day dosing cycles.

Trial Locations (20)

22031

Virginia Cancer Specialists /ID# 148584, Fairfax

27710

Duke Univ Med Ctr /ID# 148200, Durham

28034

Hospital Univ Ramon y Cajal /ID# 150799, Madrid

28040

Fundacion Jimenez Diaz /ID# 148564, Madrid

28050

Hosp Univ Madrid Sanchinarro /ID# 146039, Madrid

28078

Carolina BioOncology Institute /ID# 148583, Huntersville

29605

Greenville Hospital System /ID# 148652, Greenville

63110

Washington University-School of Medicine /ID# 151348, St Louis

75230

Mary Crowley Cancer Research /ID# 148580, Dallas

77030

Univ TX, MD Anderson /ID# 147681, Houston

78229

South Texas Accelerated Research Therapeutics /ID# 141715, San Antonio

80045

Univ of Colorado Cancer Center /ID# 148581, Aurora

85054

Mayo Clinic Arizona /ID# 148582, Phoenix

90095

University of California, Los Angeles /ID# 148586, Los Angeles

94805

Gustave Roussy /ID# 150300, Villejuif

85258-4566

Scottsdale Healthcare /ID# 151349, Scottsdale

60637-1443

University of Chicago /ID# 148579, Chicago

02215

Dana-Farber Cancer Institute /ID# 143782, Boston

10016-6402

NYU Langone Medical Center /ID# 150786, New York

19104-5502

University of Pennsylvania /ID# 148576, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY